23.4 C
New York
Sunday, July 3, 2022

MEI Pharma Inc (MEIP) stock remained bullish during the pre-market. Here’s why

MEI Pharma Inc (MEIP) stock was trading 17.56% high during the recently traded session to $0.628 and remained bullish in the pre-market after gaining 4.54% to $0.6565. The most recent news from the company came on 8 April 2022 when MEIP declared two presentations at a yearly meeting. Also, the latest SEC filing from the company was filed on 7 April 2022. MEIP filed form SC 13G/A with the SEC on 7 April 2022.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


MEI Pharma Inc is a drug organization that takes part in the clinical advancement of treatments for diseases. Currently, the firm has a market capitalization of $83.52 million and has its headquarters in San Diego, California, USA.


On 8 April 2022, MEIP declared that two banners introducing preclinical information will be introduced at the American Association for Cancer Research (AACR) Annual Meeting 2022. The first poster suggests that information from preclinical examinations with zandelisib in individual T cells and in a murine CLL model recommends that zandelisib has immunomodulatory properties on human T cells. While the second poster suggests that information from preclinical examinations assessing the mix of ME-344 with venetoclax in norm-of-care-safe AML cell lines and backslid AML patients recommend that ME-344 hinders purine biosynthesis, stifles oxidative phosphorylation, actuates apoptosis, and diminishes Mcl-1.

Moreover, on 1 April 2022, MEIP declared the award of affectation investment opportunities for a total of 0.295 million units of the organization’s normal stock to four new workers. The investment opportunities were conceded as a material instigation to each new representative tolerating work with MEI as per Nasdaq Listing Rules. The investment opportunities have a $0.6025 practice cost for every unit.

Market Overview

During last week, the S&P 500 Healthcare Index shut high while the generally S&P 500 stayed losing money. As of now, the market is confronting some genuine precariousness and instability. The Russian attack on Ukraine, China’s review issue with the U.S., worldwide store network leaps, the resurgence of Covid-19, a spike in loan costs in the midst of taking off inflation, all are unleashing devastation on the lookout. As the market remains exceptionally unsteady, financial backers have been attempting to gobble up more secure wagers. In the previous week, financial backers drove medical services to load up to new highs. Given more secure choices in medical services stocks, even the smallest news tick financial backers to mobilize a stock up and assemble a few benefits.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles